Skip to main content

Table 1 Comparison of 1 year treatment response between IL-22-high and IL-22-low group

From: Impact of serum interleukin-22 as a biomarker for the differential use of molecular targeted drugs in psoriatic arthritis: a retrospective study

Variables

IL-22 low

IL-22 high

p value

TNF-i treated group

n=12

n-12

 

DAPSA-REM

8(66.7)

5(41.6)

0.4136

DAPSA-LDA

9(75.0)

10(83.3)

1.0000

Minimal Disease Activity

8(66.7)

9(75.0)

1.0000

PASI 75

7/11(63.6)

5/11(45.4)

0.6699

PASI 90

9/11(81.8)

6 /11(54.5)

0.3615

IL-17-i-treated group

n=10

n=13

 

DAPSA-REM

9(90)

2(15.3)

*0.0006*

DAPSA-LDA

10(100)

12(92.3 %)

1.0000

Minimal Disease Activity

10(100)

6(46.1)

*0.0075*

PASI 75

7/9(77.8)

7/9(77.8)

1.0000

PASI 90

7/9(77.8)

7/9(77.8)

1.0000

  1. Data are expressed as number (%)
  2. TNF-i TNF inhibitors, IL-17-i IL-17 inhibitors, DAPSA disease activity in psoriatic arthritis, LDA low disease activity, REM remission, PASI Psoriasis Area and Severity Index
  3. *p<0.05, by chi-square test